The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Diagnosis, management, and treatment of hepatitis C†
Abstract
HCV, hepatitis C virus; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HIV, human immunodeficiency virus; anti-HCV, HCV antibody; RNA, ribonucleic acid; PCR, polymerase chain reaction; TMA, transcription-mediated amplification; FDA, Food and Drug Administration; HCC, hepatocellular carcinoma; SVR, sustained virologic response; EVR, early virologic response; ETR, end of treatment response; peginterferon, pegylated interferon; G-CSF, granulocyte colony-stimulating factor; HAART, highly active antiretroviral therapy; ddI, didanosine; GM-CSF, granulocyte-macrophage colony-stimulating factor. These recommendations provide a data-supported approach. They are based on the following: (1) a formal review and analysis of the recently published world literature on the topic (Medline search); (2) the American College of Physicians' Manual for Assessing Health Practices and Designing Practice Guidelines1 ; (3) guideline policies, including the American Association for the Study of Liver Diseases' (AASLD) Policy on the Development and Use of Practice Guidelines and the American Gastroenterological Association's Policy Statement on the Use of Medical Practice Guidelines2; the guideline procedures of the Infectious Diseases Society of America3; and (4) the experience of the authors in the specified topic. These recommendations are fully endorsed by the AASLD, the Infectious Diseases Society of America, and the American College of Gastroenterology. Intended for use by physicians, these recommendations suggest preferred approaches to the diagnostic, therapeutic and preventive aspects of care. They are intended to be flexible, in contrast to standards of care, which are inflexible policies to be followed in every case. Specific recommendations are based on relevant published information. In an attempt to characterize the quality of evidence supporting recommendations, the Practice Guidelines Committee of the AASLD requires a category to be assigned and reported with each recommendation (Table 1). The hepatitis C virus (HCV) is a major public health problem and a leading cause of chronic liver disease. In the United States, the Centers for Disease Control and Prevention estimates that there are more than 2.7 million people with ongoing HCV infection.5 HCV is the leading cause of death from liver disease in the United States.6 The purpose of this article is to provide clinicians with approaches to the diagnosis, management, and prevention of HCV infection. The optimal methods of detecting HCV infection are to screen populations for history of risk and to test selected individuals with an identifiable risk factor. With careful questioning, an HCV risk factor can be identified in more than 90% of cases.7 The primary source of HCV transmission is HCV-infected blood or blood products. In the United States, injection drug use is the chief mode of transmission, and anyone who has ever injected illicit drugs should be tested.5, 7 Persons should also be tested if they received a blood or blood component transfusion or organ transplant before 1992, when sensitive tests were first used to screen donors for HCV antibodies. Since that time, HCV infection is rarely transmitted by transfusion.8 Other potential sources of HCV transmission include exposure to an infected sexual partner or multiple sexual partners, frequent exposure to infected blood among health care workers, and perinatal exposure.9-11 Although HCV prevalence rates are consistently higher in persons with multiple sexual partners, sexual transmission of HCV between monogamous partners is rare.7 Thus, while it is common to counsel HCV-infected persons to notify their current partners of their HCV status, they should be told that the risk of sexual transmission is sufficiently low12 that many authorities do not advise use of barrier precautions (i.e., latex condoms). Testing of sexual partners, therefore, is done chiefly for reassurance. There is no need to curtail ordinary household activities except those that might result in blood exposure, such as sharing a razor or toothbrush. HCV is not transmitted by hugging and the sharing of eating utensils. Although a monogamous sexual relationship carries a low risk of transmission of HCV infection, as noted above, the risk is higher in persons involved with multiple sexual partners. Persons with hemophilia should be tested for HCV infection if blood products were received before 1987, when viral inactivation procedures were implemented. It is also advisable to test persons for HCV infection if they have evidence of otherwise unexplained elevations of aminotransferase levels (alanine and/or aspartate aminotransferases; ALT /AST), have ever been on hemodialysis, or have human immunodeficiency virus (HIV) infection.10 Other situations that have been suggested to carry a risk for HCV transmission include certain folk medicine practices (acupuncture, ritual scarification), body piercing, tattooing, and even commercial bar
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Centers for Disease Control and Prevention
(2007) · Encyclopedia of Measurement and Statistics · doi:10.4135/9781412952644.n74 · Cited by 6,444
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Histological grading and staging of chronic hepatitis
Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., Denk, H., Desmet, V., Korb, G., MacSween, R. N. M., et al. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80226-6 · Cited by 5,029
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bedossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,088
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994
Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., Kaslow, R. A., & Margolis, H. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908193410802 · Cited by 2,992
Hadziyannis, S. J., Sette, H., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Bernstein, D., Rizzetto, M., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00010 · Cited by 2,836
Poynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)07124-4 · Cited by 2,318
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection
Regev, A., Berho, M. E., Jeffers, L. J., Milikowski, C., Molina, E. G., Pyrsopoulos, N., Feng, Z.-Z., Reddy, K. R., & Schiff, E. R. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04396-4 · Cited by 2,093
The Risk of Transfusion-Transmitted Viral Infections
Schreiber, G. B., Busch, M. P., Kleinman, S. H., & Korelitz, J. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606273342601 · Cited by 1,867
Davis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S. C., Trepo, C., Shiffman, M. L., Zeuzem, S., Craxi, A., Ling, M.-H., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392102 · Cited by 1,282
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
Benhamou, Y., Bochet, M., Di Martino, V., Charlotte, F., Azria, F., Coutellier, A., Vidaud, M., Bricaire, F., Opolon, P., Katlama, C., et al. (1999) · Hepatology · doi:10.1002/hep.510300409 · Cited by 1,219
(1998) · PsycEXTRA Dataset · doi:10.1037/e547602006-001 · Cited by 1,213
Poynard, T., McHutchison, J., Manns, M., Trepo, C., Lindsay, K., Goodman, Z., Ling, M., & Albrecht, J. (2002) · Gastroenterology · doi:10.1053/gast.2002.33023 · Cited by 1,146
(1999) · PsycEXTRA Dataset · doi:10.1037/e547812006-001 · Cited by 1,131
Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., Inoue, O., Yano, M., Tanaka, M., Fujiyama, S., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00003 · Cited by 1,096
Course and outcome of hepatitis C
Hoofnagle, J. H. (2002) · Hepatology · doi:10.1002/hep.1840360704 · Cited by 1,084
Bica, I., McGovern, B., Dhar, R., Stone, D., McGowan, K., Scheib, R., & Snydman, D. R. (2001) · Clinical Infectious Diseases · doi:10.1086/318501 · Cited by 974
Graham, C. S., Baden, L. R., Yu, E., Mrus, J. M., Carnie, J., Heeren, T., & Koziel, M. J. (2001) · Clinical Infectious Diseases · doi:10.1086/321909 · Cited by 974
Sulkowski, M. S. (2000) · JAMA · doi:10.1001/jama.283.1.74 · Cited by 950
Chung, R. T., Andersen, J., Volberding, P., Robbins, G. K., Liu, T., Sherman, K. E., Peters, M. G., Koziel, M. J., Bhan, A. K., Alston, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032653 · Cited by 875
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis
Heathcote, E. J., Shiffman, M. L., Cooksley, W. G. E., Dusheiko, G. M., Lee, S. S., Balart, L., Reindollar, R., Reddy, R. K., Wright, T. L., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432302 · Cited by 874
Self-citationNishiguchi, S., Kuroki, T., Nakatani, S., Morimoto, H., Takeda, T., Nakajima, S., Shiomi, S., Seki, S., Kobayashi, K., & Otani, S. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91739-x · Cited by 857
Davis, G. L., Wong, J. B., McHutchison, J. G., Manns, M. P., Harvey, J., & Albrecht, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50364 · Cited by 819
Treatment of Acute Hepatitis C with Interferon Alfa-2b
Jaeckel, E., Cornberg, M., Wedemeyer, H., Santantonio, T., Mayer, J., Zankel, M., Pastore, G., Dietrich, M., Trautwein, C., & Manns, M. P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011232 · Cited by 800
Vento, S., Garofano, T., Renzini, C., Cainelli, F., Casali, F., Ghironzi, G., Ferraro, T., & Concia, E. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380503 · Cited by 795
Lack of Protective Immunity Against Reinfection with Hepatitis C Virus
Farci, P., Alter, H. J., Govindarajan, S., Wong, D. C., Engle, R., Lesniewski, R. R., Mushahwar, I. K., Desai, S. M., Miller, R. H., Ogata, N., et al. (1992) · Science · doi:10.1126/science.1279801 · Cited by 752
Sherman, K. E., Rouster, S. D., Chung, R. T., & Rajicic, N. (2002) · Clinical Infectious Diseases · doi:10.1086/339042 · Cited by 733
Side effects of therapy of hepatitis C and their management
Fried, M. W. (2002) · Hepatology · doi:10.1053/jhep.2002.36810 · Cited by 727
Fibrosis in Chronic Hepatitis C Correlates Significantly With Body Mass Index and Steatosis
Hourigan, L. F., Macdonald, G. A., Purdie, D., Whitehall, V. H., Shorthouse, C., Clouston, A., & Powell, E. E. (1999) · Hepatology · doi:10.1002/hep.510290401 · Cited by 674
Conry-Cantilena, C., VanRaden, M., Gibble, J., Melpolder, J., Shakil, A. O., Viladomiu, L., Cheung, L., DiBisceglie, A., Hoofnagle, J., Shih, J. W., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606273342602 · Cited by 627
The Long–Term Pathological Evolution of Chronic Hepatitis C
Yano, M., Kumada, H., Kage, M., Ikeda, K., Shimamatsu, K., Inoue, O., Hashimoto, E., Lefkowitch, J. H., Ludwig, J., & Okuda, K. (1996) · Hepatology · doi:10.1002/hep.510230607 · Cited by 598
Interferon Alfa-2a Therapy in Cryoglobulinemia Associated with Hepatitis C Virus
Misiani, R., Bellavita, P., Fenili, D., Vicari, O., Marchesi, D., Sironi, P. L., Zilio, P., Vernocchi, A., Massazza, M., Vendramin, G., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403173301104 · Cited by 583
A long-term study of hepatitis C virus replication in non-A, non-B hepatitis.
Farci, P., Alter, H. J., Wong, D., Miller, R. H., Shih, J. W., Jett, B., & Purcell, R. H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107113250205 · Cited by 571
Diagnosis and Monitoring of Hepatic Injury. I. Performance Characteristics of Laboratory Tests
Dufour, D. R., Lott, J. A., Nolte, F. S., Gretch, D. R., Koff, R. S., & Seeff, L. B. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.12.2027 · Cited by 571
Self-citationSide effects of therapy of hepatitis C and their management
Fried, M. W. (2002) · Hepatology · doi:10.1002/hep.1840360730 · Cited by 556
Berenguer, M., Prieto, M., Rayón, J. M., Mora, J., Pastor, M., Ortiz, V., Carrasco, D., Juan, F. S., Burgueño, M.-D.-J., Mir, J., et al. (2000) · Hepatology · doi:10.1053/jhep.2000.17924 · Cited by 544
Impact of Hepatitis B and C Virus on Kidney Transplantation Outcome
Mathurin, P., Mouquet, C., Poynard, T., Sylla, C., Benalia, H., Fretz, C., Thibault, V., Cadranel, J.-F., Bernard, B., Opolon, P., et al. (1999) · Hepatology · doi:10.1002/hep.510290123 · Cited by 532
Gerlach, J. T., Diepolder, H. M., Zachoval, R., Gruener, N. H., Jung, M.-C., Ulsenheimer, A., Schraut, W. W., Schirren, C. A., Waechtler, M., Backmund, M., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00668-1 · Cited by 524
Fattovich, G., Giustina, G., Favarato, S., & Ruol, A. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80184-x · Cited by 489
Persistence of Viremia and the Importance of Long–Term Follow–Up After Acute Hepatitis C Infection
Villano, S. A., Vlahov, D., Nelson, K. E., Cohn, S., & Thomas, D. L. (1999) · Hepatology · doi:10.1002/hep.510290311 · Cited by 475
Self-citationShiffman, M. L., Di Bisceglie, A. M., Lindsay, K. L., Morishima, C., Wright, E. C., Everson, G. T., Lok, A. S., Morgan, T. R., Bonkovsky, H. L., & Lee, W. M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.014 · Cited by 453
Protection against persistence of hepatitis C
Mehta, S. H., Cox, A., Hoover, D. R., Wang, X.-H., Mao, Q., Ray, S., Strathdee, S. A., Vlahov, D., & Thomas, D. L. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08435-0 · Cited by 440
Self-citationImpact of alcohol on the histological and clinical progression of Hepatitis C infection
Wiley, T. E., McCarthy, M., Breidi, L., McCarthy, M., & Layden, T. J. (1998) · Hepatology · doi:10.1002/hep.510280330 · Cited by 436
Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
Villeneuve, J.-P., Condreay, L. D., Willems, B., Pomier-Layrargues, G., Fenyves, D., Bilodeau, M., Leduc, R., Peltekian, K., Wong, F., Margulies, M., et al. (2000) · Hepatology · doi:10.1002/hep.510310130 · Cited by 410
Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV
Alberti, A., Morsica, G., Chemello, L., Cavalletto, D., Noventa, F., Pontisso, P., & Ruol, A. (1992) · The Lancet · doi:10.1016/0140-6736(92)92234-7 · Cited by 383
Hepatitis C and renal disease: an update
Meyers, C. M., Seeff, L. B., Stehman-Breen, C. O., & Hoofnagle, J. H. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00828-x · Cited by 365
Self-citationAvis, G. A. L. D., Steban, R. A. E., Ustgi, V. I. R., et al. (1998) · Cited by 363
Reddy, R. K., Wright, T. L., Pockros, P. J., Shiffman, M., Everson, G., Reindollar, R., Fried, M. W., Purdum, P. P., Jensen, D., Smith, C., et al. (2001) · Hepatology · doi:10.1053/jhep.2001.21747 · Cited by 359
Self-citationPessione, F., Degos, F., Marcellin, P., Duchatelle, V., Njapoum, C., Martinot-Peignoux, M., Degott, C., Valla, D., Erlinger, S., & Rueff, B. (1998) · Hepatology · doi:10.1002/hep.510270635 · Cited by 340
Factors predictive of a beneficial response to therapy of hepatitis C
Davis, G. L., & Lau, J. Y. (1997) · Hepatology · doi:10.1002/hep.510260721 · Cited by 325
Corrao, G., & Aricò, S. (1998) · Hepatology · doi:10.1002/hep.510270404 · Cited by 324
Schaefer, M., Schmidt, F., Folwaczny, C., Lorenz, R., Martin, G., Schindlbeck, N., Heldwein, W., Soyka, M., Grunze, H., Koenig, A., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50031 · Cited by 324
Monga, H. K., Rodriguez‐Barradas, M. C., Breaux, K., Khattak, K., Troisi, C. L., Velez, M., & Yoffe, B. (2001) · Clinical Infectious Diseases · doi:10.1086/321819 · Cited by 321
Use and interpretation of virological tests for hepatitis C
Pawlotsky, J.-M. (2002) · Hepatology · doi:10.1053/jhep.2002.36815 · Cited by 320
Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection
Lafeuillade, A., Hittinger, G., & Chadapaud, S. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03618-7 · Cited by 319
Prevention of spread of hepatitis C
Alter, M. J. (2002) · Hepatology · doi:10.1053/jhep.2002.36389 · Cited by 319
The burden of hepatitis C in the United States
Kim, R. W. (2002) · Hepatology · doi:10.1002/hep.1840360705 · Cited by 299
Sexual activity as a risk factor for hepatitis C
Terrault, N. A. (2002) · Hepatology · doi:10.1053/jhep.2002.36797 · Cited by 298
Hepatitis C and liver transplantation
Berenguer, M., López-Labrador, F. X., & Wright, T. L. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00179-9 · Cited by 284
Self-citationPoynard, T., McHutchison, J., Davis, G. L., Esteban-Mur, R., Goodman, Z., Bedossa, P., & Albrecht, J. (2000) · Hepatology · doi:10.1053/jhep.2000.19347 · Cited by 280
Ribavirin Antagonizes the Effect of Azidothymidine on HIV Replication
Vogt, M. W., Hartshorn, K. L., Furman, P. A., Chou, T.-C., Fyfe, J. A., Coleman, L. A., Crumpacker, C., Schooley, R. T., & Hirsch, M. S. (1987) · Science · doi:10.1126/science.2435003 · Cited by 279
High Rate of Infectivity and Liver Disease in Blood Donors with Antibodies to Hepatitis C Virus
Esteban, R., López-Talavera, J. C., Genescà, J., et al. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-6-443 · Cited by 279
Fibrosis and disease progression in hepatitis C
Marcellin, P., Asselah, T., & Boyer, N. (2002) · Hepatology · doi:10.1002/hep.1840360707 · Cited by 267
Treatment of Hepatitis C Infection in Injection Drug Users
Backmund, M., Meyer, K., Von Zielonka, M., & Eichenlaub, D. (2001) · Hepatology · doi:10.1053/jhep.2001.25882 · Cited by 256
Shakil, A. O., Conry-Cantilena, C., Alter, H. J., Hayashi, P., Kleiner, D. E., Tedeschi, V., Krawczynski, K., Conjeevaram, H. S., Sallie, R., Bisceglie, A. M. D., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-5-199509010-00002 · Cited by 254
Bellentani, S., Pozzato, G., Saccoccio, G., Crovatto, M., Crocè, L. S., Mazzoran, L., Masutti, F., Cristianini, G., & Tiribelli, C. (1999) · Gut · doi:10.1136/gut.44.6.874 · Cited by 246
Cost-effectiveness of Treatment for Chronic Hepatitis C Infection in an Evolving Patient Population
Salomon, J. A. (2003) · JAMA · doi:10.1001/jama.290.2.228 · Cited by 244
Molecular diagnosis of viral hepatitis
Pawlotsky, J. (2002) · Gastroenterology · doi:10.1053/gast.2002.33428 · Cited by 240
National Institutes of Health Consensus Development Conference: Management of Hepatitis C: 2002
Seeff, L. B., & Hoofnagle, J. H. (2002) · Hepatology · doi:10.1053/jhep.2002.36992 · Cited by 239
Self-citationContribution of obesity to hepatitis C-related fibrosis progression
Ortiz, V (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04352-6 · Cited by 233
Bassett, S. E., Guerra, B., Brasky, K., Miskovsky, E., Houghton, M., Klimpel, G. R., & Lanford, R. E. (2001) · Hepatology · doi:10.1053/jhep.2001.24371 · Cited by 229
Lane, H. C., Davey, V., Kovacs, J. A., Feinberg, J., Metcalf, J. A., Herpin, B., Walker, R., Deyton, L., Davey, R. T., Falloon, J., et al. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-11-805 · Cited by 228
Purpose of Quality Standards for Infectious Diseases
Gross, P. A., Barrett, T. L., Dellinger, E. P., Krause, P. J., Martone, W. J., McGowan, J. E., Sweet, R. L., & Wenzel, R. P. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.3.421 · Cited by 223
The clinical pharmacology of ribavirin.
Glue, P. (1999) · PubMed · Cited by 217
Pradat, P. (2002) · Hepatology · doi:10.1016/s0270-9139(02)00105-2 · Cited by 211
Hanafusa, T., Ichikawa, Y., Kishikawa, H., Kyo, M., Fukunishi, T., Kokado, Y., Okuyama, A., Shinji, Y., & Nagano, S. (1998) · Transplantation · doi:10.1097/00007890-199808270-00010 · Cited by 209
Is It Justifiable to Withhold Treatment for Hepatitis C from Illicit-Drug Users?
Edlin, B. R., Seal, K. H., Lorvick, J., Kral, A. H., Ciccarone, D. H., Moore, L. D., & Lo, B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450311 · Cited by 202
Use and interpretation of virological tests for hepatitis C
Pawlotsky, J.-M. (2002) · Hepatology · doi:10.1002/hep.1840360709 · Cited by 198
Noninvasive monitoring of patients with chronic hepatitis C
Fontana, R. J., & Lok, A. S. F. (2002) · Hepatology · doi:10.1053/jhep.2002.36800 · Cited by 195
Harris, D. R., Gonin, R., Alter, H. J., Wright, E. C., Buskell, Z. J., Hollinger, F. B., Seeff, L. B., & for the National Heart, L. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00012 · Cited by 194
Self-citationTreating hepatitis C in methadone maintenance patients: an interim analysis
Sylvestre, D. L. (2002) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(02)00010-8 · Cited by 189
Yao, F. Y., & Bass, N. M. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80371-2 · Cited by 182
Soriano, V., Garcia-Samaniego, J., Bravo, R., Gonzalez, J., Castro, A., Castilla, J., Martinez-Odriozola, P., Colmenero, M., Carballo, E., Suarez, D., et al. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.3.585 · Cited by 175
Transmission of hepatitis C in an isolated area in Japan: Community-acquired infection
Kiyosawa, K., Tanaka, E., Sodeyama, T., Yoshizawa, K., Yabu, K., Furuta, K., Imai, H., Nakano, Y., Usuda, S., Uemura, K., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90416-2 · Cited by 162
Stein, M. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00144-7 · Cited by 161
Wong, J. B., & Koff, R. S. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-9-200011070-00008 · Cited by 155
Sulkowski, M., Wasserman, R. B., Brooks, L., Ball, L., & Gish, R. G. (2004) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2004.00490.x · Cited by 153
Hübel, K., Dale, D. C., & Liles, W. C. (2002) · The Journal of Infectious Diseases · doi:10.1086/340221 · Cited by 150
Sexual activity as a risk factor for hepatitis C
Terrault, N. A. (2002) · Hepatology · doi:10.1002/hep.1840360713 · Cited by 148
Hepatitis C and human immunodeficiency virus infection
Thomas, D. L. (2002) · Hepatology · doi:10.1053/jhep.2002.36380 · Cited by 144
Self-citationWestin, J., Lagging, M., Spak, F., Aires, N., Svensson, E., Lindh, M., Dhillon, A. P., Norkrans, G., & Wejstål, R. (2002) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2002.00356.x · Cited by 144
National institutes of health consensus development conference: Management of hepatitis C: 2002
Seeff, L. B., & Hoofnagle, J. H. (2002) · Hepatology · doi:10.1002/hep.1840360702 · Cited by 142
Self-citationEffects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro
Hoggard, P. G., Kewn, S., Barry, M. G., Khoo, S., & Back, D. J. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1231 · Cited by 139
(1998) · PEDIATRICS · doi:10.1542/peds.101.3.481 · Cited by 135
Blatt, Mutchnick, Tong, Klion, Lebovics, Freilich, Bach, Smith, Herrera, Tobias, et al. (2000) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2000.00221.x · Cited by 133
Gossop, M., Marsden, J., Stewart, D., & Rolfe, A. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00109-5 · Cited by 126
Hui, C., Belaye, T., Montegrande, K., & Wright, T. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00004-7 · Cited by 125
Self-citationMele, A., Corona, R., Tosti, M. E., et al. (1995) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365549509047042 · Cited by 125
Noninvasive monitoring of patients with chronic hepatitis C
Fontana, R. J., & Lok, A. S.-F. (2002) · Hepatology · doi:10.1002/hep.1840360708 · Cited by 122
Prieto, M., Olaso, V., Verdú, C., Córdoba, J., Gisbert, C., Rayón, M., Carrasco, D., Berenguer, M., Higón, M. D., & Berenguer, J. (1995) · Hepatology · doi:10.1002/hep.1840220207 · Cited by 116
Briggs, M. E., Baker, C., Hall, R., et al. (2001) · Hepatology · doi:10.1053/jhep.2001.29303 · Cited by 111
Human Immunodeficiency Virus Infection, Anemia, and Survival
Moore, R. D. (1999) · Clinical Infectious Diseases · doi:10.1086/520178 · Cited by 106
Pathology of chronic hepatitis C in children
Kage, M., Fujisawa, T., Shiraki, K., Tanaka, T., Kimura, A., Shimamatsu, K., Nakashima, E., Kojiro, M., Koike, M., Tazawa, Y., et al. (1997) · Hepatology · doi:10.1002/hep.510260333 · Cited by 106
Puoti, M., Zonaro, A., Ravaggi, A., Marin, M. G., Castelnuovo, F., & Cariani, E. (1992) · Hepatology · doi:10.1002/hep.1840160404 · Cited by 96
Golub, E. T. (2004) · Journal of Heredity · doi:10.1093/jurban/jth114 · Cited by 95
Berghmans, T., Paesmans, M., Lafitte, J., Mascaux, C., Meert, A., Jacquy, C., Burniat, A., Steels, E., Vallot, F., & Jp, S. (2002) · Supportive Care in Cancer · doi:10.1007/s00520-001-0312-5 · Cited by 93
Zylberberg, H., Benhamou, Y., Lagneaux, J. L., Landau, A., Chaix, M., Fontaine, H., Bochet, M., Poynard, T., Katlama, C., Pialoux, G., et al. (2000) · Gut · doi:10.1136/gut.47.5.694 · Cited by 92
Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C
Fontaine, H., Nalpas, B., Poulet, B., Carnot, F., Zylberberg, H., Bréchot, C., & Pol, S. (2001) · Human Pathology · doi:10.1053/hupa.2001.28228 · Cited by 92
High-dose interferon-α2b treatment prevents chronicity in acute hepatitis C
Vogel, W., Graziadei, I. W., Umlauft, F., et al. (1996) · Digestive Diseases and Sciences · doi:10.1007/bf02087880 · Cited by 91
Balasekaran, R., Bulterys, M., Jamal, M. M., Quinn, P. G., Johnston, D. E., SKIPPER, B. J., Chaturvedi, S., & Arora, S. (1999) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01084.x · Cited by 80
Leonard, J. P., & Link, B. K. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30149 · Cited by 74
Severity and correlates of liver disease in hepatitis C virus-infected injection drug users
Rai, R., Wilson, L. E., Astemborski, J. A., Anania, F. A., Torbenson, M. S., Spoler, C., Vlahov, D., Strathdee, S. A., Boitnott, J., Nelson, K. E., et al. (2002) · Hepatology · doi:10.1053/jhep.2002.33151 · Cited by 73
Self-citationEddy, D. M. (1996) · JAMA · doi:10.1001/jama.1996.03530320074047 · Cited by 70
Long-Term Efficacy of α-Interferon in β-Thalassemics With Chronic Hepatitis C
Marco, V. D., Iacono, O. L., Almasio, P. L., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2207 · Cited by 65
Marcellin, P., Martinot-Peignoux, M., Elias, A., Branger, M., Courtois, F., Level, R., Erlinger, S., & Benhamou, J. P. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/170.2.433 · Cited by 63
The natural history of chronic hepatitis C infection
Strader, D. B., & Seeff, L. B. (1996) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-199604000-00006 · Cited by 59
Self-citationHepatitis C virus outside the liver
Fox, R. K. (2003) · Current Hepatology Reports · doi:10.1007/s11901-003-0005-2 · Cited by 58
Hepatitis C transmission by cosmetic tattooing in women
Sun, D., Zhang, F.-G., Geng, Y.-Q., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91172-1 · Cited by 57
Impact of chronic hepatitis B and interferon‐α therapy on growth of children
Comanor, L., Minor, J. M., Conjeevaram, H. S., Roberts, E. A., Álvarez, F., Bern, E. M., Goyens, P. J., Rosenthal, P. J., Lachaux, A., Shelton, M., et al. (2001) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2001.00262.x · Cited by 52
Tsai, J., Jeng, J., Ho, M., Chang, W., Lin, Z., & Tsai, J. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80004-3 · Cited by 51
Landau, A., Batisse, D., Piketty, C., Jian, R., & Kazatchkine, M. D. (2000) · AIDS · doi:10.1097/00002030-200008180-00025 · Cited by 46
Interferon for acute hepatitis C
Myers, R. P., Regimbeau, C., Thévenot, T., Leroy, V., Mathurin, P., Opolon, P., Zarski, J., & Poynard, T. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000369 · Cited by 45
Intrahepatic hepatitis C virus replication is increased in patients with regular alcohol consumption
Romero‐Gómez, M., Grande, L., Nogales, M. C., Fernández, M., Chavez, M., & Castro, M. (2001) · Digestive and Liver Disease · doi:10.1016/s1590-8658(01)80048-7 · Cited by 44
Treatment of Hepatitis C and Anemia in Human Immunodeficiency Virus–Infected Patients
Dieterich, D. T. (2002) · The Journal of Infectious Diseases · doi:10.1086/340199 · Cited by 35
Eddy, D. M. (1996) · JAMA · doi:10.1001/jama.275.8.650 · Cited by 34
Marcellini, M., Kondili, L. A., Comparcola, D., Spada, E., Sartorelli, M. R., Palumbo, M., & Rapicetta, M. (1997) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199711000-00009 · Cited by 26
Maintenance interferon for chronic hepatitis C: More issues than answers?
Everson, G. T. (2000) · Hepatology · doi:10.1053/jhep.2000.16216 · Cited by 26
Soriano, V., Bravo, R., García‐Samaniego, J., Castilla, J., González, J., Castro, Á., & Llibre, J. M. (1997) · PubMed · Cited by 26
Recombinant human erythropoietin in the treatment of anemic patients with hematological malignancies
Kasper, C. (2001) · Annals of Hematology · doi:10.1007/s002770100333 · Cited by 25
Barnert, R. H., Zeichhardt, H., & Habermehl, K. ‐. (1991) · Journal of Virological Methods · doi:10.1016/0166-0934(91)90080-j · Cited by 6
Cited by
Rockey, D. C., Caldwell, S. H., Goodman, Z. D., Nelson, R. C., & Smith, A. D. (2009) · Hepatology · doi:10.1002/hep.22742 · Cited by 1,997
Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis
Friedrich–Rust, M., Ong, M., Martens, S., Sarrazin, C., Bojunga, J., Zeuzem, S., & Herrmann, E. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.034 · Cited by 1,490
EASL Recommendations on Treatment of Hepatitis C 2015
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.025 · Cited by 1,156
Lin, Z.-H., Xin, Y.-N., Dong, Q.-J., Wang, Q., Jiang, X.-J., Zhan, S.-H., Sun, Y., & Xuan, S.-Y. (2011) · Hepatology · doi:10.1002/hep.24105 · Cited by 1,067
Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C. J., Fischl, M. A., Gazzard, B. G., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,033
Metadata
- Authors
- Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B.
- Venue
- Hepatology
- Published
- 2004-04
- Volume
- 39
- Issue
- 4
- Pages
- 1147-1171
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2047208492
- Cited by
- 1,709
- References
- 135
- FWCI
- 99.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.